Few provisions in the entire canon of global intellectual property law have attracted as much sustained attention, controversy and scholarly debate as Section 3(d) of the Patents Act, 1970. In the two decades since India inserted this provision into its patent statute as part of the 2005 amendment that brought the country into compliance with the Agreement on Trade-Related Aspects of Intellectual Property Rights, Section 3(d) has become simultaneously the most celebrated and the most contested feature of Indian pharmaceutical patent law. It has been praised by public health advocates, generic pharmaceutical manufacturers and developing country governments as a model of responsible IP policy a provision that harnesses the flexibilities permitted under TRIPS to ensure that patent monopolies in the pharmaceutical sector are granted only for genuine innovation and not for the kind of incremental, strategic modification of existing drugs that extends exclusivity without delivering meaningful therapeutic benefit to patients. It has been criticised by research-based pharmaceutical companies, foreign governments and industry groups as an unjustified departure from international norms, an obstacle to pharmaceutical investment and a provision whose application introduces uncertainty into the Indian patent system that is inconsistent with India’s obligations as a member of the World Trade Organisation. Understanding Section 3(d) in its full complexity requires engagement with its text and legislative history, with the Supreme Court’s landmark interpretation of it in Novartis, with the broader pharmaceutical patent ecosystem in India and with the evergreening phenomenon that the provision was specifically designed to address.
The Historical and Legislative Context
To understand Section 3(d), it is necessary to understand the position from which India approached the TRIPS-mandated introduction of product patents for pharmaceuticals. Prior to the 2005 amendment, India’s Patents Act did not permit product patents for pharmaceutical and agrochemical inventions only process patents were available, which meant that a pharmaceutical compound could be produced by a generic manufacturer through a different process without infringing any patent, even if the compound itself had been discovered and patented elsewhere. This regime, deliberately designed by India’s post-independence legislators to ensure access to affordable medicines, enabled the Indian generic pharmaceutical industry to grow into one of the largest and most export-oriented in the world, supplying affordable medicines not only to Indian patients but to developing countries across Africa, Asia and Latin America.
When TRIPS required India to introduce product patents for pharmaceuticals by January 2005, the legislative challenge was to design a regime that fulfilled India’s international obligations while preserving, to the maximum extent permitted under TRIPS, the access-to-medicines policies that had shaped the Indian pharmaceutical sector for decades. Section 3(d) was the most significant instrument through which this balance was struck. It was inserted into the Patents Act not as an incidental amendment but as a deliberate policy choice, after extensive parliamentary debate, to define the standard of patentability for pharmaceutical inventions in a manner that would prevent the worst excesses of evergreening while permitting genuine pharmaceutical innovation to be protected.
The provision was also, in significant part, a direct response to a specific filing practice that had become visible in patent offices around the world in anticipation of India’s transition to product patent protection. In the years immediately preceding 2005, pharmaceutical companies filed large numbers of applications including through the mailbox mechanism established under TRIPS Article 70.8 for new forms, new uses and new formulations of compounds that were already known. These filings were widely understood as attempts to secure patent protection over existing drugs by claiming new forms of the same active compounds, in a manner designed to extend exclusivity beyond what would have been available if product patents had existed at the time the original compound was first discovered. Section 3(d) was Parliament’s response to this practice.
The Text of Section 3(d) and Its Architecture
Section 3(d) of the Patents Act, 1970 provides that the following shall not be regarded as inventions within the meaning of the Act: the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance or of the mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant.
The provision is accompanied by an Explanation which provides that, for the purposes of Section 3(d), salts, esters, ethers, polymorphs, metabolites, pure forms, particle sizes, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substances shall be considered to be the same substance unless they differ significantly in properties with regard to efficacy.
The architecture of Section 3(d) is built around three key concepts. The first is the concept of a known substance the baseline compound or entity from which a new form or derivative is said to depart. The second is the concept of a new form the modification, whether chemical, physical or structural, that the applicant claims as the basis for the patent. The third and most consequential, is the concept of efficacy the standard by which the new form must be evaluated to determine whether the departure from the known substance is meaningful enough to justify patent protection.
The Explanation performs a critical function: it defines a list of commonly encountered pharmaceutical derivatives salts, esters, ethers, polymorphs, metabolites, pure forms and particle sizes, among others and deems them to be the same as the parent substance for the purposes of Section 3(d), unless they differ significantly in properties with regard to efficacy. This deemed equivalence is what gives Section 3(d) its anti-evergreening force. Without the Explanation, an applicant could argue that a salt form of a known compound is a chemically distinct entity and therefore not subject to the same substance bar. With the Explanation, that argument is foreclosed: the salt is presumed to be the same substance and the applicant must affirmatively demonstrate significantly different efficacy to overcome that presumption.
The Meaning of Efficacy – The Novartis Judgment
The single most important interpretive question raised by Section 3(d) is the meaning of the word “efficacy.” The provision requires that a new form of a known substance result in the “enhancement of the known efficacy” of that substance to qualify as an invention. But it does not define efficacy and the word is capable of bearing multiple meanings pharmacological activity, bioavailability, therapeutic effect in patients or some combination of these. The resolution of this question was left to the courts and it was definitively resolved, in the pharmaceutical context, by the Supreme Court of India in the landmark judgment of Novartis AG v. Union of India, (2013) 6 SCC 1.
The facts of the Novartis case are by now well known to anyone engaged with Indian pharmaceutical patent law. Novartis applied for a patent over the beta-crystalline form of Imatinib Mesylate, the active ingredient in Gleevec, a drug used for the treatment of chronic myeloid leukaemia and certain other cancers. Imatinib itself the free base had been the subject of an earlier patent and a further patent had been granted for Imatinib Mesylate, a salt form. Novartis’s application was for a specific polymorph of the mesylate salt the beta-crystalline form which Novartis contended had superior physical and chemical properties, including improved flowability and thermodynamic stability and significantly better bioavailability than the amorphous form of Imatinib Mesylate.
The Patent Office rejected the application under Section 3(d), a decision upheld by the Intellectual Property Appellate Board and Novartis challenged the rejection through a writ petition before the Madras High Court and ultimately before the Supreme Court. The Supreme Court’s judgment, delivered by a two-judge bench, is a document of extraordinary depth and consequence. On the Section 3(d) question, the Court held that efficacy, in the context of a pharmaceutical substance, means therapeutic efficacy the ability of the substance to produce the intended pharmacological result in the treatment of a patient. The Court expressly rejected the argument that enhanced bioavailability the rate and extent to which the active ingredient is absorbed and reaches the systemic circulation alone constitutes enhanced efficacy for the purposes of Section 3(d). The Court held that while bioavailability may be a relevant factor in assessing therapeutic efficacy, it is not itself therapeutic efficacy and an improvement in bioavailability does not establish enhanced efficacy unless it can be shown to translate into an enhanced therapeutic effect in patients.
On the facts, the Court found that the data submitted by Novartis including data showing thirty percent better bioavailability for the beta-crystalline form compared to the amorphous form did not establish enhanced therapeutic efficacy. The Court upheld the rejection of the application under Section 3(d), holding that the beta-crystalline form was a new form of a known substance within the meaning of the provision and that Novartis had failed to demonstrate the requisite enhancement of efficacy. The judgment confirmed India’s right to define and apply its own patentability standards within the flexibilities permitted by TRIPS and it established the therapeutic efficacy standard as the governing criterion for Section 3(d) analysis in pharmaceutical cases.
Evergreening – The Practice Section 3(d) Targets
Evergreening is the generic term used to describe a range of patent filing and litigation strategies employed by originator pharmaceutical companies to extend the effective period of market exclusivity over a drug beyond the twenty-year term of the original compound patent. The term is not a legal concept it does not appear in any statute but it describes a commercially significant reality that has been extensively documented in the pharmaceutical industry literature and by competition authorities in multiple jurisdictions.
The most common forms of evergreening involve the successive patenting of new forms of an already-patented active compound new salt forms, polymorphs, esters, metabolites, prodrugs and particle sizes each of which may attract a new twenty-year patent term from the date of filing, even though the underlying pharmacological activity of the compound was discovered and patented years or decades earlier. Other forms of evergreening involve patenting new formulations of existing drugs extended-release formulations, fixed-dose combinations or new delivery systems or new dosing regimens and methods of treatment. In each case, the patent does not cover a new chemical entity with novel therapeutic activity; it covers a modification of an existing entity that may offer some incremental benefit but whose primary commercial function is to serve as a basis for product-switching inducing prescribers and patients to move to the new, patented form before the original compound’s patent expires, thereby maintaining exclusivity and premium pricing for a further period.
The consequences of evergreening for access to medicines are significant and well-documented. Every year of additional exclusivity secured through an evergreening patent is a year in which generic manufacturers are excluded from the market and prices remain at the level set by the originator company rather than at the competitive price that generic entry would produce. In the context of essential medicines used to treat conditions such as HIV/AIDS, cancer, hepatitis and tuberculosis, these price differentials can be a matter of life and death for patients in low- and middle-income countries who cannot afford branded originator prices. Section 3(d) directly disrupts this dynamic by requiring that pharmaceutical patents in India cover only genuine therapeutic advances, not the incremental modifications that are the currency of evergreening strategy.
Section 3(d) and TRIPS – The Compatibility Debate
The pharmaceutical industry’s most fundamental challenge to Section 3(d) has been the argument that it is incompatible with India’s obligations under the TRIPS Agreement, specifically the requirement under Article 27.1 that patents shall be available for inventions in all fields of technology, provided they are new, involve an inventive step and are industrially applicable. The industry’s argument has been that Section 3(d) imposes an additional, TRIPS-incompatible requirement of enhanced efficacy on pharmaceutical inventions that is not imposed on inventions in other technology sectors and that this differential treatment violates TRIPS’s technology neutrality principle.
This argument was the central constitutional and international law question raised in the Novartis writ petition before the Madras High Court. The Madras High Court, in its 2006 judgment, declined to adjudicate the WTO compatibility question on the ground that it fell outside the court’s jurisdiction the appropriate forum for WTO compatibility disputes is the WTO dispute settlement mechanism, not domestic courts. The Supreme Court similarly did not directly resolve the WTO compatibility question, though its judgment implicitly endorses the position that Section 3(d) represents a legitimate exercise of TRIPS flexibility.
The prevailing academic and policy consensus, supported by the analysis of international trade law scholars and by the positions taken by the WHO, UNITAID and numerous civil society organisations, is that Section 3(d) is TRIPS-compatible. TRIPS Article 27.1 requires that patents be available for inventions that are new, involve an inventive step and are industrially applicable, but it leaves member states considerable latitude in defining what constitutes novelty and inventive step. The requirement that a new form of a known substance demonstrate enhanced efficacy can be characterised as a component of the inventive step analysis a legislative definition of what level of advance over the prior art constitutes a genuine inventive contribution in the pharmaceutical sector, rather than a distinct additional requirement. No WTO member has ever formally challenged Section 3(d) before the WTO dispute settlement mechanism, a fact that speaks to the legal community’s assessment of the strength of the compatibility argument.
The Application of Section 3(d) Beyond Novartis
While the Novartis judgment is the most prominent, it is not the only significant application of Section 3(d) in Indian pharmaceutical patent practice. The provision has been invoked in the examination, opposition and revocation of a large number of pharmaceutical patent applications and granted patents and the body of decisions produced by the Controller of Patents and the IPAB has developed a more granular understanding of the provision’s application in specific pharmaceutical contexts.
In the context of polymorphic forms, the consistent position of the Patent Office and the courts has been that a new polymorph of a known compound is presumed by the Explanation to be the same substance and that the applicant must produce comparative data demonstrating significantly enhanced therapeutic efficacy to overcome this presumption. Data showing improved physical stability, better manufacturability or enhanced powder flow all of which may be commercially valuable properties does not satisfy the therapeutic efficacy standard. The enhanced efficacy must manifest in clinical or pharmacological terms.
In the context of combination products, Section 3(d) intersects with Section 3(e), which excludes from patentability a substance obtained by a mere admixture resulting only in the aggregation of the properties of its components. A fixed-dose combination of two known active pharmaceutical ingredients is potentially caught by both provisions: Section 3(e) if the combination produces no synergistic effect and Section 3(d) if the combination constitutes a new form of a known substance without enhanced efficacy. Applicants seeking to patent combination products in India must therefore be prepared to demonstrate both that the combination produces a synergistic therapeutic effect and that any new form aspect of the combination satisfies the Section 3(d) standard.
In the context of prodrugs and metabolites compounds that are converted into an active drug in the body after administration the application of Section 3(d) raises more complex questions. A prodrug may be chemically distinct from the active metabolite that produces the therapeutic effect, but if the Explanation’s list of deemed equivalents is read to encompass metabolites as a category that includes prodrugs, the analysis under Section 3(d) becomes demanding. The developing examination practice suggests that prodrugs are assessed on a case-by-case basis, with attention to whether the prodrug itself constitutes a meaningful therapeutic advance or whether it is merely a delivery vehicle for a known active compound.
The Broader Access to Medicines Impact
The practical impact of Section 3(d) on access to medicines in India and globally has been substantial and well-documented. By preventing the grant of patents over incremental pharmaceutical modifications without genuine therapeutic advance, the provision has kept the Indian market open to generic competition at a significantly earlier point than would otherwise have been the case. This has directly benefited Indian patients, who have access to generic versions of many critical medicines at prices a small fraction of those charged in markets where evergreening patents have been upheld.
The impact extends beyond India’s borders. The Indian generic pharmaceutical industry enabled by the competitive generic market that Section 3(d) helps to maintain is a primary supplier of affordable medicines to low- and middle-income countries globally, particularly through procurement programmes such as those operated by UNITAID, the Global Fund and PEPFAR. Medicines for the treatment of HIV/AIDS, multi-drug-resistant tuberculosis, hepatitis C and several cancers have been made available to patients in developing countries at affordable prices precisely because Indian generic manufacturers have been able to produce them without being blocked by evergreening patents.
The Industry Perspective and the Counterarguments
The research-based pharmaceutical industry’s critique of Section 3(d) rests on several distinct arguments that deserve serious engagement, even where they ultimately do not alter the conclusion that the provision is sound policy. The industry argues, first, that incremental pharmaceutical innovation the development of improved forms, formulations and delivery systems for existing drugs has genuine clinical value that Section 3(d) undervalues. A new salt form with better bioavailability may enable a lower dose and thereby reduce side effects. An extended-release formulation may improve patient compliance and clinical outcomes. A new polymorph with superior stability may be more suitable for use in tropical climates where the original form degrades. These are real benefits and the industry argues that the therapeutic efficacy standard is too narrow to capture them.
The industry also argues that the uncertainty created by Section 3(d) the difficulty of predicting whether any given pharmaceutical modification will be held to satisfy the therapeutic efficacy standard discourages investment in pharmaceutical R&D focused on the Indian market and that this disincentive has long-term consequences for India’s emergence as an innovation-oriented pharmaceutical economy rather than merely a generics producer.
These are not trivial concerns and they have informed ongoing debates about whether the therapeutic efficacy standard should be defined more precisely, whether a broader efficacy concept that encompasses improvements in safety, tolerability or patient convenience should be adopted and whether the provision should be applied differently to different categories of pharmaceutical modification. The Supreme Court in Novartis itself acknowledged that the question of what constitutes efficacy in non-pharmaceutical contexts where therapeutic effect is not the relevant measure remains open and that the provision may have different applications in different technology sectors.
Section 3(d) as a Model for Other Jurisdictions
One of the most significant dimensions of the Section 3(d) story is the influence that India’s approach has had on patent policy debates in other developing countries. In the years following the Novartis judgment, a number of developing and middle-income countries including Argentina, Brazil, Ecuador and several others either adopted similar provisions in their own patent legislation or explicitly cited Section 3(d) as a model for national patent reform. International organisations including the WHO, UNCTAD and the UN Secretary-General’s High-Level Panel on Access to Medicines have pointed to Section 3(d) as an example of the kind of policy tool that developing countries can and should use to calibrate their patent systems in a manner responsive to public health imperatives.
This influence is itself a measure of Section 3(d)’s significance. A provision that was drafted in response to specific filing practices in a specific national context has become a touchstone of global IP policy, a reference point in debates about the appropriate scope of pharmaceutical patent protection that extends far beyond India’s borders.
Conclusion
Section 3(d) is more than a statutory exclusion from patentability. It is a declaration of values a statement by the Indian legislature that the patent system exists to reward genuine innovation, that incremental pharmaceutical modifications do not constitute the kind of advance that justifies a patent monopoly unless they deliver meaningful therapeutic benefit and that the right of patients to access affordable medicines is a consideration that the patent system must take seriously and not merely accommodate at the margins. Its enactment was deliberate, its text carefully crafted, its application by the Supreme Court in Novartis authoritative and its impact on pharmaceutical patent practice in India and globally profound.
The evergreening debate that Section 3(d) has crystallised will not be resolved by any single statute or judgment. It reflects a fundamental tension between the patent system’s function as an incentive for innovation and its potential as an instrument of monopoly that, without adequate calibration, can exclude patients from medicines they need. Section 3(d) represents India’s answer to that tension an answer that has proved both legally defensible and practically consequential and that has placed India at the centre of one of the most important intellectual property debates of the twenty-first century.
References
- The Patents Act, 1970 https://ipindia.gov.in
- Novartis AG v. Union of India, (2013) 6 SCC 1 https://main.sci.gov.in
- Novartis AG v. Union of India, Madras High Court, 2006 https://hcmadras.tn.nic.in
- Bayer Corporation v. Natco Pharma Ltd., Controller of Patents, 2012 https://ipindia.gov.in
- TRIPS Agreement, WTO https://www.wto.org/english/docs_e/legal_e/27-trips.pdf
- WHO Access to Medicines and TRIPS Flexibilities https://www.who.int/health-topics/medicines
- UNITAID Patent Landscape Reports https://unitaid.org
- UN High-Level Panel on Access to Medicines, 2016 https://www.unsgaccessmeds.org
- National IPR Policy, 2016, DPIIT https://dpiit.gov.in
- Manual of Patent Office Practice and Procedure https://ipindia.gov.in
Compulsory Licensing Copyright Act Copyright Act 1957 Copyright Infringement Copyright Law Copyright Rules Deceptive Similarity Descriptive Marks India Goodwill Indian IP Framework Indian Patent Law Indian Trademark Law Intellectual Property Law IP Law India Patent Claims Patent Enforcement Patent Infringement Patent law Patent Revocation Patent Rule Patents Act 1970 Pharmaceutical Patents Section 3 Section 29 The Patent Act 1970 Trademark Infringement Trademark Registration Trade Marks Act 1999 Trade Marks Rules 2017 TRIPS Compliance